Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 117 Publications

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 M3HucGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVy3NkBp MoToSG1UVw>? NHf1OGZKSzVyPUCuNFAxODdizszN M{ezO|E4QTV4MEiw
K562 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\0[|dpPzJiaB?= M3;5XmROW09? NWPP[XFsUUN3ME2wMlAxOSEQvF2= NWXhclJJOTd7NU[wPFA>
M07e M3u0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoO1O|IhcA>? MoruSG1UVw>? MkLKTWM2OD1yLkCwNVIh|ryP NXz2bpF2OTd7NU[wPFA>
ALL3 NUXkZWVjS3m2b4TvfIlkKEG|c3H5 MYewMlHPxE1? NUXPeFN1PzJiaB?= M2nQPWROW09? Ml3sTWM2OD1yLkCwNFQh|ryP Mo\4NVk5QDl3NEC=
CML MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTOZY81OjBibXnu M1u2VmROW09? MkDmTWM2OD1yLkCwNUDPxE1? M1X5SlE6OjF7MEG2
BA/F3 NEXqNW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUe3NkBp NVvyN5RGTE2VTx?= MlX1TWM2OD14LkW4PUDPxE1? MmHpNlMxQDh4NES=
BA/F3 MlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml7qO|IhcA>? NUXwWVhqTE2VTx?= NVLNR3hvUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSmO{LVHicEBOOzVzVDDteZRidnRid3n0bEBKSzVyIH;mJFAvODByOEROwG0> MkDJNlMxQDh4NES=
BA/F3 NUfleHROT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\QO|IhcA>? M1PFcGROW09? NIiwTlZKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{B4cWymIIT5dIUhSmO{LVHicEB4cXSqIFnDOVAhd2ZiMD6wNFQ2|ryP NYDPPFV1OjNyOEi2OFQ>
BA/F3 M330Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXP6O5pxPzJiaB?= MknQSG1UVw>? MmPXTY5lfWOnczDhcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEKDL1[zJINmdGy|IHX4dJJme3OrbnegRoNzNUGkbDDUN|E2USCvdYThcpQhf2m2aDDJR|UxKG:oIEGuO|E1|ryP MoHGNlMxQDh4NES=
BA/F3 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rHV|czKGh? M2LaUGROW09? Mn3BTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTjR6NmOgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNFnPxE1? NEXrTYUzOzNyMUewNy=>
BA/F3 NUfqRo1DT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzs[VR{PzJiaB?= M170OmROW09? MoDHTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTJ3NVugcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwN|LPxE1? NHvwVmQzOzNyMUewNy=>
BA/F3 M{fwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLmO|IhcA>? MULEUXNQ MWfJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEBIOjVyRTDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMEC1Ne69VQ>? M2OxNFI{OzBzN{Cz
BA/F3 NYTTdZJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\EVJR1PzJiaB?= NFPXSoZFVVOR NUTBNVZHUW6mdXPld{BkgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFLDVk1CSkxiUUK1NmghdXW2YX70JIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCwMlAxQM7:TR?= MnLyNlM{ODF5MEO=
BA/F3 NUW1dm9LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoD3O|IhcA>? NG\ScFFFVVOR M33xZmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV|NUnWJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFE{|ryP NGexbI4zOzNyMUewNy=>
BA/F3 NHvqT3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfYNotpPzJiaB?= NYq4UnE1TE2VTx?= M2TCZmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yC5aXzkJJR6eGViQlPSMWFDVCCjc4Pld5Nm\CCjczDndo94fGhiSX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yMEG5{txO NGjHdFUzOzNyMUewNy=>
BA/F3 NVnKXppLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fjeVczKGh? M{T4SGROW09? Mn\TTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhYTJ3M1igcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNlPPxE1? MmK3NlM{ODF5MEO=
BA/F3 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXe3NkBp MV7EUXNQ NHzwTodKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCWM{G1TUBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIEOuOu69VQ>? NEjkNHczOzNyMUewNy=>
BA/F3 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn34O|IhcA>? Mn7VSG1UVw>? Mlv4TY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghUW6qaXLpeIlwdiC5aYToJGlEPTBib3[gNk42|ryP MUeyN|MxOTdyMx?=
T cell MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjobWk4OiCq Mk\0SG1UVw>? MV;Jcohq[mm2czDhcpRqKEOGMz2gZY5lKGGwdHmgR2QzQC2rbnT1Z4VlKFRiY3XscEBxem:uaX\ldoF1cW:wIIfpeIghUUN3MDDv[kAxNjByM988US=> M33SeFE4OTV2NUGy
WiDr M1jNRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fTdFczKGh? MVPEUXNQ MoDrTWM2OD1yLkC1NkDPxE1? MmmyNVU3OTV3MUK=
PC3 NH3oOHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYC3NkBp NGfuOnpFVVOR NIT3e|JKSzVyPUCuNFA6PCEQvF2= M3\neFE2PjF3NUGy
MDA-MB-231 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX23NkBp NGjwRZBFVVOR MWPJR|UxRTBwMEGyJO69VQ>? NWmxfIRVOTV4MUW1NVI>
Hs578T NX\jRXJES3m2b4TvfIlkKEG|c3H5 MYq3NkBp MXnEUXNQ NYHmWGRMT0l3ME2wMlA{KM7:TR?= MUOyOFAyPTN{Nx?=
HMEC NXjaNHp3S3m2b4TvfIlkKEG|c3H5 M1nQ[lczKGh? NHnoW5NFVVOR M{Dx[mdKPTB;MT64JO69VQ>? M3PYU|I1ODF3M{K3
DU145 M3u4VGN6fG:2b4jpZ{BCe3OjeR?= M2jtclczKGh? MXnEUXNQ NYC2N4FpT0l3ME2wMlE3KM7:TR?= MWqyOFAyPTN{Nx?=
U251 NGnPSJFEgXSxdH;4bYMhSXO|YYm= NYeyRpJ4PzJiaB?= NIXRNXdFVVOR NH3NfXNIUTVyPUKuPFEh|ryP NU\LVYtEOjRyMUWzNlc>
NCI60 MXzDfZRwfG:6aXOgRZN{[Xl? M4POeFczKGh? M2K3N2ROW09? MUXHTVUxRTVwNzFOwG0> M4HrZVI1ODF3M{K3
MALME-3M MlPLR5l1d3SxeHnjJGF{e2G7 NGHXfIM4OiCq MUHEUXNQ MYLHTVUxRTZwNkGg{txO MkHsNlQxOTV|Mke=
KM12 Mn75R5l1d3SxeHnjJGF{e2G7 NIfxSHE4OiCq NV\ORlNzTE2VTx?= MkLIS2k2OD15LkS0JO69VQ>? MVeyOFAyPTN{Nx?=
SW620 M1jr[mN6fG:2b4jpZ{BCe3OjeR?= MVi3NkBp MlnqSG1UVw>? MmTFS2k2OD16LkSzJO69VQ>? M{jzdVI1ODF3M{K3
RXF 393NL NXjWVWdmS3m2b4TvfIlkKEG|c3H5 NWK5PXk{PCCmYYnz MnzqSG1UVw>? M3TPOGlEPTB;MD6wNlE4KM7:TR?= MnnaNlMzPTNyN{S=
LXFA 983L M{HrOWN6fG:2b4jpZ{BCe3OjeR?= M1TxXVQh\GG7cx?= NV7kWIlsTE2VTx?= MWrJR|UxRTBwMEW2OUDPxE1? MlfiNlMzPTNyN{S=
PRXF DU145 NWXmSWJkS3m2b4TvfIlkKEG|c3H5 MoHrOEBl[Xm| MYTEUXNQ MX;JR|UxRTBwME[yN{DPxE1? M2P2[VI{OjV|MEe0
PAXF 1657L NXnteWU5S3m2b4TvfIlkKEG|c3H5 MUC0JIRigXN? MmCwSG1UVw>? MWLJR|UxRTBwMUKxJO69VQ>? MWmyN|I2OzB5NB?=
CXF 1103L M3yzN2N6fG:2b4jpZ{BCe3OjeR?= NFLafpY1KGSjeYO= NFT0[pNFVVOR NIrxRWdKSzVyPUSuN|Yh|ryP MmrsNlMzPTNyN{S=
GXF251L NHTkU3VEgXSxdH;4bYMhSXO|YYm= M{DiflQh\GG7cx?= NFvCXXZFVVOR NHKxPXNKSzVyPUKuNlUh|ryP MV:yN|I2OzB5NB?=
NCI-H23 MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rSOFczKGh? NXjXW29OTE2VTx?= MlzHTWM2OD1{LkK3JO69VQ>? NUC0Rm1{OjN3MkGwNlA>
HCT116 NXz4NYF5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:3NkBp MlfFSG1UVw>? M4fIcWlEPTB;Mj6zJO69VQ>? M2fQeVI{PTJzMEKw
MCF7 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUewfmlqPzJiaB?= MYLEUXNQ MU\JR|UxRTJwNUeg{txO NWLRdnl7OjN3MkGwNlA>
NCI-H460 M4PqO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVG3NkBp NYjlVHB1TE2VTx?= NVPDbpV3UUN3ME24Mlk6KM7:TR?= M3TOWlI{PTJzMEKw
DLD1 M1\BdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3XO|IhcA>? NYO5PG15TE2VTx?= M3;weWlEPTB;ND62JO69VQ>? M{XKfVI{PTZ5OU[w
NCI-H661 NYLnSHRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfjOJk4OiCq M2r1fGROW09? MoKyTWM2OD15Lkig{txO Ml2yNlM2Pjd7NkC=
A549 NVjkOXVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDqO|IhcA>? MlTxSG1UVw>? NIDYcohKSzVyPUiuNkDPxE1? MXOyN|U3Pzl4MB?=
U937 NH3NWWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHlcVk4OiCq NI\QUG1FVVOR NVnTOHN5UUN3ME2xNk4zKM7:TR?= MlPFNlM2Pjd7NkC=
HEK293 MXzGeY5kfGmxbjDBd5NigQ>? MkXRNVDDqM7:TR?= MonBSG1UVw>? NITONGZKdmS3Y3XzJIJqdmSrbnegZYZncW6rdImgeI8hcHWvYX6g[pVtdC2uZX7neIghUGm|LYTh[4dm\CCPeYSxJItqdmG|ZTDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IIfpeIghUUN3MDDv[kAxNjB4M988US=> NXPaO2lUOjJ5N{C2NVA>
HUVEC NXPEeldIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;TNE4yPcLizszN Mnz0O|IhcA>? NFTq[o9FVVOR NITOOWxKdmS3Y3XzJIFvfGmjbnfpc4dmdmmlIHHjeIl3cXS7IHnuJGhWXkWFIHPvMYN2dHS3cnXkJJdqfGhidnHzZ5Vt[XJic33vc5RpKG23c3Ps[UBk\WyuczDhd5Nme3OnZDDhd{BKdmirYnn0bY9vKG:oIHPlcIwh\3Kxd4ToJIF1KDBwMUWgeW0> NXS4VnBTOjJ6NUO5PVM>
HUVEC MUTGeY5kfGmxbjDBd5NigQ>? M33EZlE2yqEQvF2= MUG3NkBp NVrreopmTE2VTx?= NV;kd29EUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO|ZXSgZZMhUW6qaXLpeIlwdiCxZjDu[ZR4d3KtIH\vdo1ifGmxbjDheEAyNjhidH:gNVUhfU1? NH62RYQzOjh3M{m5Ny=>
Plasmodium falciparum MmPPSpVv[3Srb36gRZN{[Xl? NYPzRYdNOTEEoN88US=> MXexOUBucW5? M2O4NWROW09? MnzsTY5pcWKrdIOgVIxie22xZHn1cUBn[WylaYDhdpVuKHC{b3zp[oVz[XSrb36gZpkhcW6qaXLpeIlv\yC2aHWgSpVv[3Srb36gc4YhWG[FRGDLNUBxem:2ZXnuJJdqfGhiSVO1NEBw\iBzLkG3{txO M2jsVVI1PTVyM{Ow
PC3 NVO4WnNjTnWwY4Tpc44hSXO|YYm= M1nhfFAvOSEQvF2= M3n1d|UhcA>? NXTIcnN{TE2VTx?= NYDRV3RJUW6qaXLpeJMhcHWvYX6gVGM{KGOnbHygZYRp\XOrb36gZZQhOTByIH7N MVuxPVQ3Ojl5NR?=
DU145 M4X4PWZ2dmO2aX;uJGF{e2G7 MXOwMlEh|ryP MUO1JIg> NVvtTINUTE2VTx?= MorRTY5pcWKrdIOgbJVu[W5iRGWxOFUh[2WubDDh[Ihme2mxbjDheEAyODBibl2= M{PmeVE6PDZ{OUe1
PC3 MXjLbY5ie2ViQYPzZZk> M{nze|AvOSEQvF2= NIS5d2I2KGh? NXjtVIxmTE2VTx?= NUfLdWdUUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDQR|Mh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKFO{YzDZOFE3KGyndnXsJIF1KDFyMDDuUS=> NX7nfIVvOTl2NkK5O|U>
DU145 NFjpeFVMcW6jc3WgRZN{[Xl? MnG1NE4yKM7:TR?= NUfMTIFEPSCq M32yNGROW09? NGPX[3RKdmirYnn0d{BkW3KlIHnuJIh2dWGwIFTVNVQ2KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDwbI9{eGixconsZZRm\CCVcnOgXVQyPiCuZY\lcEBifCBzMECgcm0> MlLRNVk1PjJ7N{W=
PC3 M3jie2tqdmG|ZTDBd5NigQ>? M4rpelAvOSEQvF2= MX[1JIg> M1nG[WROW09? MXnJcohq[mm2czDjV5JkKGmwIHj1cYFvKFCFMzDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YheGixc4Doc5J6dGG2ZXSgSmFMKFl3N{[vXVU4PyCuZY\lcEBifCBzMECgcm0> NILjZ5oyQTR4Mkm3OS=>
DU145 NVrONm97U2mwYYPlJGF{e2G7 NXL2bJA6OC5zIN88US=> MUO1JIg> M1XrVmROW09? NX7KWJl7UW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiRlHLJHk2PzZxWUW3O{Bt\X[nbDDheEAyODBibl2= NYTTW3k1OTl2NkK5O|U>
Huh7 NITkOmNCdnSrdnnyZYwhSXO|YYm= NWjjb|FJOi53IN88US=> NHu2WJI1KGSjeYO= M2P0RWROW09? Ml3RTY5pcWKrdIOgeolz[Wxic4Dy[YFlKGmwIFTlcod2\SC4aYL1d{1qdm[nY4Tl[EBpfW2jbjDIeYg4KGOnbHzzJIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDv[kB3cXKjbDDlcpZmdG:yZTDwdo91\WmwIIfpeIhqdiCyZYLpcpVkdGWjcjDy[Ydqd25iYYSgNk42KHWP MnXBNVc{PjB4N{[=
C6/36 NH76SVhCdnSrdnnyZYwhSXO|YYm= MX[yMlUh|ryP M4PPPFQh\GG7cx?= M33JNWROW09? M2\MNGlvcGmkaYTzJJZqemGuIIPwdoVi\CCrbjDE[Y5ofWVidnnyeZMucW6oZXP0[YQh[XOrYX6geIlo\XJibX;zdZVqfG9iQ{[vN|Yh[2WubIOgZZN{\XO|ZXSgZZMh[WOldX31cIF1cW:wIH;mJJZqemGuIHXueoVtd3CnIIDyc5RmcW5id3n0bIlvKHCncnnueYNt\WG{IILl[4lwdiCjdDCyMlUhfU1? MkTSNVc{PjB4N{[=
U937 Mn73SpVv[3Srb36gRZN{[Xl? Mn;UNUDPxE1? MXexJIg> MoHvSG1UVw>? M1jVXnJm\HWlZYOgZoF{[WxiVF7GZYxxcGFicnXs[YF{\SCrbjDoeY1idiCXOUO3JINmdGy| M1T6b|E4Pjh2MEm5
U937 Ml3vSpVv[3Srb36gRZN{[Xl? NXPmVYNYOSEQvF2= MVGxJIg> NIrBbmxFVVOR NWrLS2F4WmWmdXPld{BNWFNvaX7keYNm\CCWTl\hcJBp[SC{ZXzlZZNmKGmwIHj1cYFvKFV7M{egZ4VtdHN? MUCxO|Y5PDB7OR?=
murine mast cell MVjGeY5kfGmxbjDBd5NigQ>? NEn6[ZIyKM7:TR?= MlToNlQhcA>? MVnEUXNQ M{LuW2lvcGmkaYTzJIFvfGmpZX6tbY5lfWOnZDDJUFYhe2WlcnX0bY9vKGmwIFnnSUBxemmvZXSgcY92e2VibXHzeEBk\WyuczDheEAyKHWP M3XqPFE4Pjh2MEm5
BV-173 NXmydIh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTYfZF[UUN3ME2wMlAxODByMEGwPUDPxE1? MVTTRW5ITVJ?
K-562 Ml[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTBwMECwNFAxOjZ4IN88US=> MWfTRW5ITVJ?
BL-70 M{DYV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmryTWM2OD1yLkCwNFAxODh{MjFOwG0> MmHDV2FPT0WU
EM-2 NXXHOIZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWT2S4hKUUN3ME2wMlAxODByMUC4JO69VQ>? NVv2Z3N3W0GQR1XS
LAMA-84 NVrScG1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TZXGlEPTB;MD6wNFAxODN{MTFOwG0> MULTRW5ITVJ?
MEG-01 MkjVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j3e2lEPTB;MD6wNFAxODl6IN88US=> NFvqZVZUSU6JRWK=
EoL-1-cell MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTBwMECwNFE{OSEQvF2= MYDTRW5ITVJ?
CTV-1 Mlu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjhcVRjUUN3ME2wMlAxODB2MESg{txO NIGzXWNUSU6JRWK=
TE-15 M3X1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rIemlEPTB;MD6wNFU5QSEQvF2= MXPTRW5ITVJ?
NOS-1 M{[2XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnDXJlKSzVyPUCuNFA3OTNizszN MkDTV2FPT0WU
D-336MG NW\vOFBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHJTWM2OD1yLkCwOlMh|ryP NGDXR|BUSU6JRWK=
LB1047-RCC NXW0XppJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXXJR|UxRTBwMEC5PFkh|ryP M1GwdHNCVkeHUh?=
LB996-RCC MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3pXmhtUUN3ME2wMlAxQTlzIN88US=> M3e2XHNCVkeHUh?=
SW982 MmfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlX1TWM2OD1yLkCxNVE2KM7:TR?= MX7TRW5ITVJ?
TK10 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnSTWM2OD1yLkCxNVc1KM7:TR?= M33iTnNCVkeHUh?=
A704 MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwMEG0PVEh|ryP Mki0V2FPT0WU
TE-8 NUT5PHh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HJd2lEPTB;MD6wNVU4PiEQvF2= NYi3elhMW0GQR1XS
DOHH-2 NWTSRYJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnvDTWM2OD1yLkCxO|E6KM7:TR?= MlfpV2FPT0WU
HOP-62 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnj1TWM2OD1yLkCxPFM1KM7:TR?= M3zNVHNCVkeHUh?=
TE-12 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXGZ3E6UUN3ME2wMlAyQDZzIN88US=> NYHNWG9bW0GQR1XS
KGN MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXyTWM2OD1yLkCxPVQzKM7:TR?= MnWxV2FPT0WU
NCI-H1648 NFu3bJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrlTWM2OD1yLkCyNFEyKM7:TR?= Mlq3V2FPT0WU
OS-RC-2 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFXtOphKSzVyPUCuNFIxOyEQvF2= NWmyZ5RmW0GQR1XS
GB-1 MojKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU[y[5VyUUN3ME2wMlAzOTV5IN88US=> NYHGOoRIW0GQR1XS
RXF393 NWGzS|BZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTBwMEKzOVch|ryP MnezV2FPT0WU
LC-2-ad MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXm3PFdNUUN3ME2wMlAzPTh4IN88US=> NFLFRplUSU6JRWK=
KS-1 NHz3R3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIr2Z3NKSzVyPUCuNFI4OyEQvF2= M4fQbHNCVkeHUh?=
ETK-1 NWjNeIpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nTUmlEPTB;MD6wNlg{OiEQvF2= M2HhPHNCVkeHUh?=
SW954 M2niOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkThTWM2OD1yLkCyPVI4KM7:TR?= NGXCUItUSU6JRWK=
Becker MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXPPGJJUUN3ME2wMlA{ODB|IN88US=> MUXTRW5ITVJ?
MZ1-PC M3TReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnqc2d{UUN3ME2wMlA{OTF7IN88US=> NXXCOW9MW0GQR1XS
ES6 MmfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrCTWM2OD1yLkCzNVk{KM7:TR?= Ml7pV2FPT0WU
KURAMOCHI M3HlXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTBwMEO0PFch|ryP MYrTRW5ITVJ?
CGTH-W-1 NGPLVnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3z3ZmlEPTB;MD6wN|U1QCEQvF2= NGnmSoZUSU6JRWK=
VA-ES-BJ NECxNo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwMEO5NFIh|ryP M3;Sc3NCVkeHUh?=
LXF-289 NV;rWmRrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Sw[GlEPTB;MD6wN|k2PiEQvF2= M4HCb3NCVkeHUh?=
MPP-89 NV\nUW5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnXW4RKSzVyPUCuNFQxPDlizszN MXfTRW5ITVJ?
SW872 NXrGenFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwMESxOlEh|ryP M2Dwe3NCVkeHUh?=
SNB75 M{XPN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1OwOGlEPTB;MD6wOFQ{PSEQvF2= MUTTRW5ITVJ?
PSN1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPkPVVKSzVyPUCuNFQ1PzRizszN Mo\IV2FPT0WU
LB831-BLC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwMES2NFkh|ryP NYSzd3R5W0GQR1XS
MFH-ino MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYi2U4lQUUN3ME2wMlA1PzJ2IN88US=> NHnqbGJUSU6JRWK=
TGBC24TKB M3TGU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnHNTWM2OD1yLkC0O|YyKM7:TR?= NHOydpVUSU6JRWK=
A388 MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TZS2lEPTB;MD6wOVA6PSEQvF2= MWrTRW5ITVJ?
BB30-HNC MmXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrDTWM2OD1yLkC1OFM4KM7:TR?= NGnlc4VUSU6JRWK=
GI-ME-N NXuwTWR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwME[xNVgh|ryP NYHXVmtYW0GQR1XS
TGBC1TKB MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTBwME[xOlQh|ryP M1vme3NCVkeHUh?=
TE-10 NF7NR2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr4bW1KSzVyPUCuNFY{PTdizszN MnfsV2FPT0WU
A498 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTBwMEeyPFQh|ryP M{LV[HNCVkeHUh?=
TE-11 M332ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\QO2lEPTB;MD6wO|g2QCEQvF2= NXXOTVRVW0GQR1XS
BB65-RCC MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHxTWM2OD1yLkC4NlI4KM7:TR?= NWrIWYduW0GQR1XS
C2BBe1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr4bJV{UUN3ME2wMlA5OzB6IN88US=> NHvPWm1USU6JRWK=
NCI-H747 NWXXUZY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XBTGlEPTB;MD6wPFM3OiEQvF2= M{PSZnNCVkeHUh?=
IST-MES1 MnXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4H4W2lEPTB;MD6wPFU2OiEQvF2= MkjNV2FPT0WU
KALS-1 M17DW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWj3WmN{UUN3ME2wMlA6PDlizszN NEL4OVdUSU6JRWK=
GCIY MmLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvheYxKSzVyPUCuNFk3PTZizszN NFLpcGVUSU6JRWK=
RL95-2 M1vlemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETRVHBKSzVyPUCuNVA{QCEQvF2= MUXTRW5ITVJ?
TE-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfz[2lKSzVyPUCuNVA2PCEQvF2= NF[yT|lUSU6JRWK=
NCI-H1355 M2HVO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{HKUmlEPTB;MD6xNVAzQCEQvF2= MlfPV2FPT0WU
SW962 M4jN[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHFTWM2OD1yLkGxNlkzKM7:TR?= NIn1XmZUSU6JRWK=
KLE M2PyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIq1WJBKSzVyPUCuNVE{OTdizszN NFzQT4lUSU6JRWK=
MC116 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\Ie3Z5UUN3ME2wMlEyPDFizszN MVXTRW5ITVJ?
NMC-G1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTBwMUG2NFYh|ryP M{W0XHNCVkeHUh?=
KU812 NXryNVNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonvTWM2OD1yLkGxPFg{KM7:TR?= NGDOfHNUSU6JRWK=
COLO-829 NH7NS3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTBwMUKyNVMh|ryP NVXzc4ZZW0GQR1XS
NTERA-S-cl-D1 NWTEeHJJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVfuT2FjUUN3ME2wMlEzOjh|IN88US=> NVzhW4dkW0GQR1XS
IST-MEL1 M{m0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVS1SFBMUUN3ME2wMlE{PDVizszN MknEV2FPT0WU
MLMA MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwMUSwN|Ih|ryP M4H4XnNCVkeHUh?=
LS-123 NH\1VmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zFdGlEPTB;MD6xOFA3PCEQvF2= NYTMSZFYW0GQR1XS
LB2518-MEL NXXUSGRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HFVGlEPTB;MD6xOFE3OiEQvF2= M1fPbnNCVkeHUh?=
NB69 NV7lbYlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDETWM2OD1yLkG0OFM3KM7:TR?= NGm4Zo9USU6JRWK=
8-MG-BA MkXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnkTWM2OD1yLkG1OFU5KM7:TR?= NU\xe|ViW0GQR1XS
K5 NWC2[IprT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TrVWlEPTB;MD6xOlQ5QSEQvF2= NFrXcHFUSU6JRWK=
KINGS-1 NIPCTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUPaO3U3UUN3ME2wMlE3PjZ4IN88US=> MnXBV2FPT0WU
SF268 NIHnVVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTBwMUe0NFQh|ryP MYnTRW5ITVJ?
PF-382 NUjyfHd4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfqTWM2OD1yLkG3Olc5KM7:TR?= NWi5[3VrW0GQR1XS
SH-4 NULjWmh7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVH4b|h4UUN3ME2wMlE5PDF|IN88US=> MYjTRW5ITVJ?
NALM-6 M{C5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NED2NI1KSzVyPUCuNVkzQTVizszN M3rwOHNCVkeHUh?=
CP66-MEL NGrwSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWf4OGVMUUN3ME2wMlE6PTNzIN88US=> NHnQdHBUSU6JRWK=
697 MlHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3vZ5dQUUN3ME2wMlE6QTh5IN88US=> M3v3W3NCVkeHUh?=
CP67-MEL MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIKxfmZKSzVyPUCuNlA1QDhizszN MnvUV2FPT0WU
DSH1 NIC5bFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHZTmVXUUN3ME2wMlI1ODBzIN88US=> NGfRV4RUSU6JRWK=
HCE-4 M3zOdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;VTWM2OD1yLkK2OFM6KM7:TR?= MYXTRW5ITVJ?
MZ2-MEL M3jV[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjrTWM2OD1yLkK4OVM4KM7:TR?= NVvuS41tW0GQR1XS
BL-41 NFrDc3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXmx[np3UUN3ME2wMlI6OTJ|IN88US=> MUXTRW5ITVJ?
HUTU-80 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTBwM{G0NkDPxE1? Ml:zV2FPT0WU
LOXIMVI M{TTR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHX[ZZKUUN3ME2wMlMyPTB|IN88US=> NFn1TYZUSU6JRWK=
no-10 MofYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIf3eodKSzVyPUCuN|E6OzFizszN NHSzPIVUSU6JRWK=
KARPAS-422 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYnJR|UxRTBwM{O5PVch|ryP NEj0eodUSU6JRWK=
SW684 NHizV|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwM{S5PEDPxE1? MVTTRW5ITVJ?
SF126 M4XwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDlWWVQUUN3ME2wMlM2PDFizszN NVjVNm5iW0GQR1XS
D-263MG NUK5fmI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHYRmdKSzVyPUCuN|YzOjRizszN NYDOT5pwW0GQR1XS
OVCAR-4 NYj1NmExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HYW2lEPTB;MD6zO|Q{OyEQvF2= MnjlV2FPT0WU
BB49-HNC MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTBwM{i1PVkh|ryP NU\iNmxNW0GQR1XS
ONS-76 NFnIc|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DYSWlEPTB;MD60Nlk2OSEQvF2= MVzTRW5ITVJ?
MZ7-mel NEL4cWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwNEe5NVEh|ryP MYrTRW5ITVJ?
RCC10RGB MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvxTWM2OD1yLkS5NVEh|ryP NEmwSY9USU6JRWK=
BOKU MofBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;4[5RJUUN3ME2wMlQ6OTN|IN88US=> NIexWplUSU6JRWK=
no-11 NWS3cFllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWn0WWM1UUN3ME2wMlUxOjJ6IN88US=> NFzQWJlUSU6JRWK=
IST-SL2 MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvyTWM2OD1yLkWwN|AzKM7:TR?= NEDNVWFUSU6JRWK=
RKO NGLSOGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;Td4NKSzVyPUCuOVI6PjZizszN MWDTRW5ITVJ?
HT-144 M3G5UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPOTGVOUUN3ME2wMlU{PjB7IN88US=> MV;TRW5ITVJ?
NCI-H446 MnLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzPRpNKSzVyPUCuOlI4PiEQvF2= MljmV2FPT0WU
QIMR-WIL MlvxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fuUGlEPTB;MD63NFYzQSEQvF2= MoLoV2FPT0WU
MHH-PREB-1 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTBwN{S0Olkh|ryP M4DkPHNCVkeHUh?=
EW-16 M3PiW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTyTWM2OD1yLke2NVc5KM7:TR?= NGexNXhUSU6JRWK=
EW-24 NIDsRWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTBwN{ixOlUh|ryP M1nrdXNCVkeHUh?=
LB373-MEL-D NWXYWJlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTBwOEK1NFgh|ryP NFXSW4NUSU6JRWK=
TE-9 M3rCdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2XZ[WlEPTB;MD64O|U{OiEQvF2= MnH3V2FPT0WU
A3-KAW MkDyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwOUi0OVIh|ryP MknOV2FPT0WU
A101D MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlL1TWM2OD1zLkCzNFQ{KM7:TR?= NXS2eGRqW0GQR1XS
OCUB-M NH7QVFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTFwMES0NVIh|ryP NV7uUGdLW0GQR1XS
ES4 MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jlTGlEPTB;MT6wOVE1PSEQvF2= M1nwbnNCVkeHUh?=
TE-6 M2jsNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILrS3JKSzVyPUGuNlEzOjZizszN M{nkS3NCVkeHUh?=
D-502MG NIK0cFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTFwMkOzO|Yh|ryP NIrKNZlUSU6JRWK=
KNS-42 NHLRT|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHSclNsUUN3ME2xMlI1PDF{IN88US=> NEjuOoVUSU6JRWK=
SNU-C2B NIPWW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnZSYJnUUN3ME2xMlMxPTh7IN88US=> MkDFV2FPT0WU
NCI-H1838 NV7uXHl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzoTWM2OD1zLkOwO|M{KM7:TR?= MWnTRW5ITVJ?
NKM-1 M2T3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjKWXFLUUN3ME2xMlMxQDV7IN88US=> MXPTRW5ITVJ?
GI-1 NYLkT|NrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzRTWM2OD1zLkO2NlIh|ryP M3zoRnNCVkeHUh?=
NB5 M2rG[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWPMW4k6UUN3ME2xMlM6QDJ5IN88US=> NXjoe5BiW0GQR1XS
CAS-1 NFvzd|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYL6SlBrUUN3ME2xMlQxQTl{IN88US=> MoDaV2FPT0WU
HCE-T M3PTe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnjCTWM2OD1zLkW2O|E1KM7:TR?= NIDqZWtUSU6JRWK=
SBC-1 MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjTRlFKSzVyPUGuOVc6QDRizszN NUHrb3NmW0GQR1XS
JiyoyeP-2003 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYm4TWlPUUN3ME2xMlc{PDZ4IN88US=> MXrTRW5ITVJ?
TE-5 NW\YVoJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTFwN{mxN|kh|ryP M1vx[XNCVkeHUh?=
CAN NYTJRolKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTFwOEKyOVIh|ryP M3vpUHNCVkeHUh?=
SK-UT-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nqcGlEPTB;Mj6xOlY6OyEQvF2= NXXOcI9rW0GQR1XS
JVM-2 NF[1SoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfEfnU1UUN3ME2yMlM3Ojh2IN88US=> NXLkW2ZMW0GQR1XS
LB771-HNC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEnmd2JKSzVyPUKuOVc2PTFizszN MXTTRW5ITVJ?
NCCIT M4D5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jmdWlEPTB;Mj64OlYyPiEQvF2= MXLTRW5ITVJ?
NCI-H2126 NYXqT|BDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXW0[WwzUUN3ME2yMlg4PTV{IN88US=> NYDrW4ZtW0GQR1XS
Calu-6 Mm\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlK5TWM2OD1|LkC1O|QyKM7:TR?= Ml3vV2FPT0WU
SK-LMS-1 NXnMXFVGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTNwMUG4PFYh|ryP NVfKU3p4W0GQR1XS
ARH-77 NXrVNnQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFm1co1KSzVyPUOuOFY6OTVizszN MYLTRW5ITVJ?
NB17 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTNwNkO4OFch|ryP NV3EdZJjW0GQR1XS
A253 MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HXdGlEPTB;Mz63N|I1PiEQvF2= NWDPcVlvW0GQR1XS
OPM-2 MmLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzXN3ZKSzVyPUSuNlc3QDVizszN MkT6V2FPT0WU
MV-4-11 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFLBenJKSzVyPUSuN|Y1PTRizszN NXjDTHNEW0GQR1XS
SR MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTRwNEm5OVQh|ryP NXX1Z2RpW0GQR1XS
KG-1 M2jxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7ofWtKSzVyPUSuOlA5PDVizszN MYfTRW5ITVJ?
OCI-AML2 NGmzXIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHuzTolKSzVyPUWuPFYyPTRizszN NX\tSlduW0GQR1XS
D-247MG MmXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\lUohKSzVyPU[uNVI2OTlizszN M1fhPXNCVkeHUh?=
DJM-1 Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYrjVolVUUN3ME22MlQ5PTV6IN88US=> MUXTRW5ITVJ?
RPMI-6666 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTtRlhKSzVyPUeuNlcxPjdizszN MVTTRW5ITVJ?
KARPAS-45 MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTdwNUG2O|Eh|ryP NXz4UlZ1W0GQR1XS
LP-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTdwNUS3PFIh|ryP NILNVXZUSU6JRWK=
RS4-11 NXXXW3FRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvHS25PUUN3ME23MlY2Pzh5IN88US=> M3mwdnNCVkeHUh?=
DU-4475 M2\Gc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1GxWWlEPTB;OD6yNVY2OiEQvF2= MnLKV2FPT0WU
MONO-MAC-6 M4Xad2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\C[mNKSzVyPUiuNlcxPjZizszN NHTrVGtUSU6JRWK=
NCI-SNU-16 NXzMdXNxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjudHhmUUN3ME24MlU3OTJ6IN88US=> NUHSb2M{W0GQR1XS
SJSA-1 NHXTNYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HSbGlEPTB;OD63NlgxPSEQvF2= NVnnV4kxW0GQR1XS
MMAC-SF MoWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrlTWM2OD16Lke5N|A4KM7:TR?= MWjTRW5ITVJ?
SK-NEP-1 NF:5SHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRThwOEmxOVUh|ryP MlvxV2FPT0WU
J-RT3-T3-5 M{PuT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnlTlBKSzVyPUiuPVY2OjlizszN MWHTRW5ITVJ?
SKM-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTlwMEG3N|Qh|ryP NETld2NUSU6JRWK=
LB2241-RCC NVv2XmtuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWq0cJZwUUN3ME25MlAzODF{IN88US=> NUf0OoxiW0GQR1XS
SIG-M5 NEGyV|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTlwMEK0PVMh|ryP NF7ab2lUSU6JRWK=
EVSA-T NEfGd2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TTd2lEPTB;OT6yO|c6OyEQvF2= MkfvV2FPT0WU
GT3TKB MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:3V4FHUUN3ME25MlM2PTR4IN88US=> NHfYe5ZUSU6JRWK=
NB6 M3j6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DOeGlEPTB;OT65NlI2QSEQvF2= MoTJV2FPT0WU
EHEB NGTVfJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTFyLkC2OVYh|ryP M1jMWHNCVkeHUh?=
HEL MlrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\pTWM2OD1zMD60O|c3KM7:TR?= NWXBTWZLW0GQR1XS
ALL-PO Mm\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUSyR5FKUUN3ME2xNE44QTN6IN88US=> NU\UWGc2W0GQR1XS
TGW M1\6eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjMTWM2OD1zMT6yPFI5KM7:TR?= NWHlZ2U1W0GQR1XS
BC-3 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHZTWM2OD1zMj6xNVM5KM7:TR?= M4[3b3NCVkeHUh?=
IA-LM NHrXSYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4izdmlEPTB;MUKuOFQ1PSEQvF2= M37p[HNCVkeHUh?=
UACC-257 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3lSXhKSzVyPUGyMlkyQThizszN M1LVR3NCVkeHUh?=
KP-N-YS NE\PRVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHVSGFKSzVyPUGyMlkzQDNizszN NYLSdGk2W0GQR1XS
Raji MmDXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX7WN5ZUUUN3ME2xN{44PDl5IN88US=> M3HGbXNCVkeHUh?=
SF539 NV7UNYJNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Xqe2lEPTB;MUOuPFU2PyEQvF2= Mn;iV2FPT0WU
DMS-153 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXqwU2hlUUN3ME2xOE4xODJ6IN88US=> M2DEb3NCVkeHUh?=
L-540 NV[z[I5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\uNIhvUUN3ME2xOU4xPjd{IN88US=> M4\GfXNCVkeHUh?=
MN-60 M2DvZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\2R2lEPTB;MUWuNVk4QSEQvF2= NI\4e5pUSU6JRWK=
RPMI-8866 M{nxXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTF5LkS0OVQh|ryP Mn;aV2FPT0WU
NCI-H510A MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXVWZVsUUN3ME2xPU4{QTd|IN88US=> M{TwXnNCVkeHUh?=
NB13 NYLDZ5hZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnf6TWM2OD1zOT60PFc4KM7:TR?= MlvFV2FPT0WU
HAL-01 NHHPbGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NW\Nc4NHUUN3ME2xPU44PTR|IN88US=> NX\pVotmW0GQR1XS
NCI-H720 M3m4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTJyLkK3N|Mh|ryP M3P2cXNCVkeHUh?=
REH M2[zN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTJyLk[zOVch|ryP NH3o[nhUSU6JRWK=
KNS-81-FD MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfwTWM2OD1{Mz6xOFYh|ryP MYnTRW5ITVJ?
HC-1 NVr6Z3Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTJ2LkW1OVEh|ryP MXXTRW5ITVJ?
NCI-H2141 MoO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1na[GlEPTB;MkSuO|c2PCEQvF2= NIfoeo1USU6JRWK=
MOLT-4 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETVTVdKSzVyPUK2MlY4PTNizszN MUfTRW5ITVJ?
OMC-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF[0dm1KSzVyPUK3MlE1OjJizszN NGCz[VRUSU6JRWK=
LC-1F MonDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rZSWlEPTB;MkeuN|I1PSEQvF2= NX72Xpd4W0GQR1XS
NCI-H1304 NHvoO|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTJ6LkG2Nlgh|ryP MXLTRW5ITVJ?
BC-1 MmnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDuTWM2OD1{OD62OVEh|ryP MUnTRW5ITVJ?
NCI-H64 NEXCbGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTOTWM2OD1{OT62NlU{KM7:TR?= NV\WdJVHW0GQR1XS
MOLT-16 NH3hb|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHjTWM2OD1{OT62NlkzKM7:TR?= NH\OWVNUSU6JRWK=
U-87-MG M2W3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTNyLke2OkDPxE1? NVXnRW57W0GQR1XS
GAK MmfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTNzLkK2PFYh|ryP NV7OPGtuW0GQR1XS
ES8 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTN{LkGyOVIh|ryP M1nnNnNCVkeHUh?=
HCC1599 NWHpcFdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPLTWM2OD1|Mj6zN|I2KM7:TR?= NGraTlhUSU6JRWK=
EB-3 Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkf4TWM2OD1|ND6zNVE4KM7:TR?= MmPLV2FPT0WU
HCC1187 MnLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXEU|RNUUN3ME2zOU45ODV{IN88US=> NV:0bXZtW0GQR1XS
SK-PN-DW NWDrc5VwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTN4LkG5OFMh|ryP MVfTRW5ITVJ?
JVM-3 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\TTWM2OD1|Nz6yN|M5KM7:TR?= MWLTRW5ITVJ?
HCC2157 MlrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDrTWM2OD1|Nz65PVQ3KM7:TR?= NFT4VYRUSU6JRWK=
A4-Fuk NYDmPY05T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1KzOGlEPTB;M{iuNVAxQSEQvF2= MVPTRW5ITVJ?
COR-L279 NWPFW3FIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHXTFRKSzVyPUSwMlI5PTFizszN NGnEUJhUSU6JRWK=
DEL MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3ReHVuUUN3ME20NU46ODh4IN88US=> NHv3TIlUSU6JRWK=
NCI-H1395 M1y1c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DIWGlEPTB;NEKuNFE3OyEQvF2= NVWz[2d1W0GQR1XS
MHH-NB-11 M1vQTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml6wTWM2OD12Mz6wPFE5KM7:TR?= NIfFe|lUSU6JRWK=
NCI-H2107 Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mme5TWM2OD12Mz60PFQ3KM7:TR?= NVj6VWExW0GQR1XS
NEC8 MnOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzEeWpzUUN3ME20OE4{OzZizszN NGS5W2FUSU6JRWK=
COLO-684 NX\IeWRxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NES2ZmpKSzVyPUS2MlIzPThizszN M4iz[nNCVkeHUh?=
LS-411N M1PGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfqOYNKSzVyPUS4MlQ4PDhizszN MoHxV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
phospho-c-Abl(Tyr245) / phospho-c-Src(Tyr416); 

PubMed: 23049975     


Protein levels of phosphorylated c-Abl (Tyr245), c-Abl, phosphorylated c-Src (Tyr416), c-Src, and GAPDH in NSC-34 cells overexpressing human wild-type or mutant SOD1s treated with various concentrations of dasatinib were measured by western blot. Cells were cultured in serum-free culture medium with doxycycline (Dox, 2 µg/ml), and western blot was performed at 24 h after dasatinib addition.

p27 / p21; 

PubMed: 20145167     


Dasatnib induced cell cycle arrest. Dasatinib induced growth arrest, shown as a cell cycle distribution graph in the lower panel, correlated with increased p27 and p21 levels. Western blotting for levels of p27 and p21 was performed on protein lysates of THP-1 cells treated for 48 hours with indicated doses of dasatinib or DMSO. Detection of actin served as control for comparable protein loading.

p-FAK / p-STAT3; 

PubMed: 23721490     


The effect of dasatinib in cell signalling. Western blot analysis with phosphorylated Src, FAK, Stat3, Akt and MAPK in HCC cell lines after 24 hours treatment of dasatinib. The cell lines were arranged according to their IC50 to dasatinib. The top three were most sensitive, the bottom 3 were least sensitive.

cleaved caspase 3; 

PubMed: 20145167     


Dasatinib induced apoptosis. Dasatinib causes apoptosis in Mo7e-KitD816H cells as detected by cleavage of caspase 3. Whole cell lysates were prepared after 24 hour treatment with dasatinib. Caspase 3 and cleaved capase 3 were analyzed by western blotting. Actin serves as loading control.

23049975 20145167 23721490
Growth inhibition assay
IC50; 

PubMed: 23721490     


9 HCC cell lines were exposed to the dedicated concentrations of dasatinib for 72 hours, and IC50 was tested by MTS. Results represent the mean (± SD) of three experiments.

23721490
Immunofluorescence
SRC / Met; 

PubMed: 26517812     


Immunocytochemistry of SRC and Met localization. Cellular localization of SRC and Met following treatment for 48 h with dasatinib, crizotinib or combination in A. LN-18 and B. U373 cells. Scale bar denotes 10 μm. Nuclei were visualized by DAPI while SRC and Met were labeled with a fluorescein and Texas-red conjugated secondary antibodies, respectively.

F-actin / Actinin-4 / Paxillin; 

PubMed: 31053734     


Conditionally immortalized differentiated podocytes treated for one-hour with 2 µM kinase inhibitor were stained for F-actin (phalloidin), α-actinin-4, paxillin, and nuclei (Hoechst 33342) to assess cytoskeletal and focal adhesion architecture (scale bars = 50 µm). Podocytes treated with dasatinib showed a marked decrease in cell-to-cell contacts, cell size and number of focal adhesions.

α-tubulin; 

PubMed: 26517812     


Combination of dasatinib and crizotinib impedes the formation of the α-tubulin-labeled mitotic spindle. LN-18 cells were treated with dasatinib 0.2 μM, crizotinib 4 μM or their combination for 48 h. Mitotic spindle were visualized using α-tubulin antibody conjugated to a fluorescein-labeled secondary antibody. Nuclei were stained by DAPI. The scale bar denotes 10 μm.

26517812 31053734
ELISA
TNF-α; 

PubMed: 17684099     


U937 cells were differentiated with vitamin D3, pretreated with the indicated concentrations of drugs for 1 h and stimulated with LPS for 6 h. TNF-α secretion was measured by ELISA. The graph shows the mean of two experiments done in duplicate.

E-selectin; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of E-selectin was determined using ELISA (n = 3, ±SEM).

VCAM-1; 

PubMed: 31110200     


HAoECs were treated with DMSO, a dual FAK/Pyk2 inhibitor (PF-271, 2.5 μM), a Src inhibitor (Dasatinib, 1 μM), or a FAK inhibitor (PF-228, 10 μM) for 1 h prior to TNF-α (10 ng/ml, 6 h) stimulation. Expression levels of VCAM-1 was determined using ELISA (n = 3, ±SEM).

17684099 31110200
In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

+ Expand
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
in solvent
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03885830 Not yet recruiting CML Chronic Phase|CML (Chronic Myelogenous Leukemia|CML - Philadelphia Chromosome|Chronic Myeloid Leukemia|Chronic Myeloid Leukemia Chronic Phase UNC Lineberger Comprehensive Cancer Center May 2019 --
NCT03885830 Not yet recruiting CML Chronic Phase|CML (Chronic Myelogenous Leukemia|CML - Philadelphia Chromosome|Chronic Myeloid Leukemia|Chronic Myeloid Leukemia Chronic Phase UNC Lineberger Comprehensive Cancer Center May 2019 --
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03878524 Not yet recruiting Breast Cancer|Prostate Cancer|Pancreatic Cancer|Acute Myelogenous Leukemia OHSU Knight Cancer Institute|Oregon Health and Science University|Prospect Creek Foundation March 14 2019 Phase 1
NCT03318770 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --
NCT03318770 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • Answer:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • Question 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • Answer:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products4

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID